Invention Grant
- Patent Title: Antibodies to TGF-β
-
Application No.: US16197802Application Date: 2018-11-21
-
Publication No.: US10781252B2Publication Date: 2020-09-22
- Inventor: Steven R. Ledbetter , Celia Patricia Hart , Robert G. Holgate , Lutz U. Jermutus , Catriona L. Buchanan , Alexander R. Duncan , Donna K. Finch
- Applicant: Genzyme Corporation , Optein, Inc.
- Applicant Address: US MA Cambridge US DE Wilmington
- Assignee: Genzyme Corporation,Optein, Inc.
- Current Assignee: Genzyme Corporation,Optein, Inc.
- Current Assignee Address: US MA Cambridge US DE Wilmington
- Agency: Steptoe & Johnson LLP
- Agent Z. Ying Li; Mauricio Alvarez
- Main IPC: C07K16/22
- IPC: C07K16/22 ; A61P13/12 ; A61K39/00 ; A61K39/395

Abstract:
The present invention relates to antibody molecules, in particular antibody molecules that bind Transforming Growth Factor beta (TGFβ), and uses thereof. More particularly, the invention relates to antibody molecules that bind and preferably neutralise TGFβ1, TGFβ2 and TGFβ3, so-called “pan-specific” antibody molecules, and uses of such antibody molecules. Preferred embodiments within the present invention are antibody molecules, whether whole antibody (e.g. IgG, such as IgG1 or IgG4) or antibody fragments (e.g. scFv, Fab, dAb).
Public/Granted literature
- US20190177406A1 Antibodies to TGF-Beta Public/Granted day:2019-06-13
Information query